Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI Equity Ratio

The Equity Ratio of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Nov 15, 2026 is 69.52 %. In the previous year, Equity Ratio was 68.75 % — a change of 1.12% (higher).

Equity Ratio

69.52 %

YoY

1.12%

Last updated:

Equity Ratio of Laboratorios Farmaceuticos ROVI is 2025 69.52 % . Equity Ratio of Laboratorios Farmaceuticos ROVI was 2024 68.75 % . It decreases by 1.12% higher compared to the previous year.

The Laboratorios Farmaceuticos ROVI Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
71.39 EUR
Jan 1, 2019
63.06 EUR
Jan 1, 2020
65.05 EUR
Jan 1, 2021
64.28 EUR
Jan 1, 2022
59.18 EUR
Jan 1, 2023
67.43 EUR
Jan 1, 2024
68.75 EUR
Jan 1, 2025
69.52 EUR
The Laboratorios Farmaceuticos ROVI Equity Ratio history
YEAREquity RatioYoY
69.52 %+1.12%
68.75 %+1.96%
67.43 %+13.95%
59.18 %-7.94%
64.28 %-1.19%
65.05 %+3.16%
63.06 %-11.66%
71.39 %+11.12%
64.24 %+0.83%
63.72 %+2.02%
62.45 %+2.99%
60.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

Equity Ratio of Laboratorios Farmaceuticos ROVI is 69.52 % in 2025.

Equity Ratio of Laboratorios Farmaceuticos ROVI changed from 68.75 % to 69.52 %, representing a 1.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Laboratorios Farmaceuticos ROVI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI